Use Of Cannabidiol In The Treatment Of Epilepsy.

  • Published: Apr 6, 2017
  • Earliest Priority: Jun 17 2014
  • Family: 38
  • Cited Works: 0
  • Cited by: 0
  • Cites: 0
  • Additional Info:

The full document isn't yet available to us from the patent office, but we've found a related patent (family member) to use for our images and PDF.


The present disclosurerelates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering withetiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q;, Jeavons syndrome; Myoclonic Absence Epilepsy;Neuronal ceroid lipofuscinoses(NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).


Information currently unavailable.

CPC Classifications
IPC Classifications
Family Member PDF
Family Member Preview
These are the images from a related family member, as the full document isn't yet available to us from the patent office.
Document History
  • Publication: Apr 6, 2017
  • Application: Jun 17, 2015
    MX MX 2016016460 A
  • Priority: Jun 17, 2015
    GB GB 2015051776 W
  • Priority: Jun 17, 2014
    GB GB 201410771 A

Sign in to the Lens